References 1. Habra, MA et al. Outcomes by Site of Metastasis for Patients With Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib Versus Placebo: Results from a Phase 3, Randomized Trial. 15th International Thyroid Congress 2015; Presented at the 15th International Thyroid Congress, October 2015
2. SmPC Lenvima (updated June 2015). Available
at: http://www.medicines.org.uk/emc/medicine/30412 . Accessed: October 2015
3. Tahara, M et al. Efficacy and Safety of Lenvatinib by Body Mass Index in Patients
With 131I-Refractory Differentiated Thyroid Cancer From the Phase 3 SELECT Study. 15th
International Thyroid Congress 2015; Presented at the 15th International Thyroid
Congress, October 2015
4. Brose, M et al. Lenvatinib and the Effect of Age on Overall Survival for Patients
With Radioiodine-refractory Differentiated Thyroid Cancer. 15th International Thyroid
Congress 2015, October 2015
5. Haymart, R et al. Understanding the Relationship Between Age and Thyroid Cancer. The
Oncologist 2009; 14: 216-221
6. Tremblay, G et al. Number-Needed-to-Treat (NNT) Analysis of Therapies In
Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC) Using Indirect
Comparison. 15th International Thyroid Congress 2015; Presented at the 15th
International Thyroid Congress, October 2015
7. Haddad, R et al. Incidence and Timing of Common Adverse Events in Lenvatinib-treated
Patients With Radioiodine-refractory Thyroid Cancer From the SELECT Trial. 15th
International Thyroid Congress 2015; Presented at the 15th International Thyroid
Congress, October 2015
8. Abouzaid, S et al. Characteristics of Patients on Lenvatinib With Treatment-emergent
Hypertension in the SELECT Trial. 15th International Thyroid Congress 2015, October
2015
9 . Thyroid Cancer Basics. 2011. Available at: http://www.thyca.org. Accessed: October
2015
10. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib
Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015; 6:89-94
11. Wu P et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Drug Discovery Today 2015; 1-6
12 . Schlumberger M, et al. Relationship Between Thyroid-Stimulating Hormone Levels and
Outcomes from the Randomized, Double-Blind, Phase 3 Study of (E7080) Lenvatinib in
Differentiated Cancer of the Thyroid (SELECT). Available at:
https://endo.confex.com/endo/2015endo/webprogram/Paper20459.html. Accessed: October
2015
13. Brito J et al. BMJ 2013; 347
14. Cabanillas ME, Dadu R. Optimizing therapy for radioactive iodine-refractory
differentiated thyroid cancer : Current state of the art and future directions.
Minerva Endocrinol. 2012 Dec; 37(4):335-356.
15 . EUCAN 2015. http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35.
Accessed: October 2015
16. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol. 2012;23 (suppl
7):vii110-vii119.
Date of preparation: October 2015
Job code: Oncology-UK0064
CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller, 20 Oct. (0) - 7908314 155 / +44(0) 7951 078 795, Cressida_Robson@eisai.net /Ben_Speller@eisai.net ; Tonic Life Communications, Alex Davies / EmmaCoughlan, +44 (0)7720 496 472 / +44(0) 7772 534 646,Alex.Davies@toniclc.comEmma.Coughlan@toniclc.com
